Evidence map›Paper›PMID 32751888›Full record

ArticleJournal of clinical medicine2020

Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017.

Maria Angela Samis Zella, Dirk Bartig, Lennard Herrmann, Gesine Respondek, Günter Höglinger, Ralf Gold, Dirk Woitalla, Christos Krogias, Lars Tönges

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Comorbid pathologies and their impact on progressive supranuclear palsy: current view.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  2. Observational
  3. Article
  4. Disease modification in Parkinsonism: obstacles and ways forward.Journal of neural transmission (Vienna, Austria : 1996) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Maria Angela Samis ZellaDepartment of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44801 Bochum, Germany.
Dirk BartigDRG MARKET, D-49069 Osnabrück, Germany.
Lennard HerrmannDepartment of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44801 Bochum, Germany.
Gesine RespondekDepartment of Neurology, Hannover Medical School, 30625 Hannover, Germany.
Günter HöglingerDepartment of Neurology, Hannover Medical School, 30625 Hannover, Germany.
Ralf GoldDepartment of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44801 Bochum, Germany.
Dirk WoitallaDepartment of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44801 Bochum, Germany.
Christos KrogiasDepartment of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44801 Bochum, Germany.ORCID 0000-0003-2965-4051
Lars TöngesDepartment of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44801 Bochum, Germany.ORCID 0000-0001-6621-144X
St. Josef-Hospital · DEGerman Center for Neurodegenerative Diseases · DEMedizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progressive supranuclear palsy (PSP) belongs to the disease spectrum of Parkinsonian syndromes. Due to the chronic and progressive neurodegenerative course of the disease, PSP patients often have to be hospitalized to undergo diagnostic and therapeutic measures. The dynamics and characteristics of PSP inpatient treatment in Germany have not been investigated thus far. The current study analyzed trends of inpatient treatment in Germany for the years 2010-2017 based on the German DRG statistics ("diagnostic-related groups") in the category G23.- (other degenerative diseases of the basal ganglia) and with special focus on PSP (G23.1). Inpatient case numbers of the G23.- category comprised a total of 21,196 patients from 2010-2017, whereas the PSP subcategory (G23.1) amounted to 10,663 cases. In the analyzed time period, PSP patient numbers constantly increased from 963 in 2010 to 1780 in 2017 with yearly growth rates of up to 20%. Similar trends were observed for other Parkinsonian syndromes such as multiple system atrophy (MSA). Differentiating PSP inpatients by gender demonstrated a higher proportion of males (55-60%) in comparison to female patients for the entire observation period. The average age of hospitalized PSP patients over these years was between 72.3 and 73.4 years without relevant differences for gender. The most common comorbidities consisted of cardiovascular, neurological, muscular and urological disorders. In summary, the analysis demonstrates that PSP patients are increasingly hospitalized in Germany and the current concepts of stationary care have to differentiate standard practices for Parkinson's disease (PD) to also address the needs of patients with PSP and other Parkinsonian syndromes.

Indexed as

Parkinsonian syndromesParkinson’s diseaseprogressive supranuclear palsyPSP

Identifiers

PMID32751888
PMCPMC7465231
OpenAlexW3046708884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.